Compare AMWL & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | RANI |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2M | 106.9M |
| IPO Year | 2020 | 2021 |
| Metric | AMWL | RANI |
|---|---|---|
| Price | $9.91 | $0.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $7.40 | ★ $7.50 |
| AVG Volume (30 Days) | 62.0K | ★ 634.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.06 | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | N/A | $274.77 |
| Revenue Next Year | $4.24 | $79.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $3.71 | $0.39 |
| 52 Week High | $9.96 | $3.87 |
| Indicator | AMWL | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 62.56 | 35.15 |
| Support Level | $8.06 | $0.45 |
| Resistance Level | $9.96 | $0.83 |
| Average True Range (ATR) | 0.54 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 76.09 | 20.70 |
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.